Drugs / SGB-3383
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06995326 | Jun 2025 → Aug 2026 overdue | — | Suzhou Sanegene Bio Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGB-3383 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06995326 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered SGB-3383” NCT06995326 ↗ |